Lexeo Therapeutics(LXEO) - 2023 Q4 - Annual Results
Exhibit 99.1 Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Lexeo announces 121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data from a subset of the second dose cohort of SUNRISE-FA, a Phase 1/2 clinical trial of LX2006 for the treatment of Friedreich's ataxia (FA) cardiomyopathy, showing positive change in post-treatmen ...